Cart, 0 Items

Subtotal (USD):$0.00
Your cart is empty
After you’ve made a selection, review it here before checking out.
Search titles
Cover of GENERIC PHARMACUETICAL PATENT AND FDA LAW SUB
Quick look inside:

Generic Pharmacuetical Patent and FDA Law, 2024-2025 ed.

Publisher:

Thomson West
Format
Purchase option
One-time purchase
One-time purchase of this edition. Updates or new editions must be purchased separately.
$1,041.00
now
Quantity
Availability:
In stock
eBook - One-time purchase with no updates
$1,041.00 USD
now

Proview Generic Pharmaceutical Patent And Fda Law 2024-2025 Entitlement

Format

eBook

Purchase option

One-time purchase with no updates

Quantity

1

Total

$1,041.00

/now

Product details
Description

Generic Pharmaceutical Patent and FDA Law covers Food and Drug Administration (FDA) approval of generic drugs and the interaction of patents and FDA law. A practitioner’s guide, it walks the reader through the stages of drug approval, identifying the

Publisher:Thomson West
Service Number:43162743
Publication date:2024-09-19
Practice area:Intellectual property law
Jurisdiction:General
External Product Title:Proview Generic Pharmaceutical Patent And Fda Law 2024-2025 Entitlement
Update frequency:No updates
Update Format:N/A
Available Formats:eBook
Shelf space:0 in
Author:


ProView is the way to read Thomson Reuters eBooks and eLooseleafs, published primarily for legal, accounting, human resources, and tax professions. The Thomson Reuters ProView web-based application is accessed via your browser. With the new ProView web-app, offline capability is now available from your browser. The web application has a responsive design and is compatible with desktop, laptop, and mobile devices.

 

Get started with ProView training

Related Resources

Publication Frequency:
No updates
Updated Format:
N/A

Shashank Upadhye

Mr. Upadhye is the former vice president and global head of intellectual property for Apotex, Inc., a global generic drug company based in Toronto, Ontario, Canada. He has practiced law with various law firms in Boston and Chicago, specializing in brand-side